Evidence map›Paper›PMID 38700282›Full record

ArticleJournal of diabetes investigation2024

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.

Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tetsuaki InokuchiInokuchi Medical Clinic, Fukuoka, Japan.ORCID https://orcid.org/0009-0000-2893-4436
Yoshihide FukumotoFukumoto Clinic, Kagoshima, Japan.
Gendai LeeDiabetes and Endocrinology, Diabetes and Kidney Medical Corporation Gendai Clinic, Fukuoka, Japan.
Yoshifumi YokomizoYokomizo Clinic, Fukuoka, Japan.
Kokichi TanakaTanaka Medical Clinic, Fukuoka, Japan.
Michiko ChosaWakamatsu Memorial Hospital, Kagoshima, Japan.
Masaru DoiDoi Clinic, Kumamoto, Japan.
Noboru TamakiTamaki Clinic, Miyazaki, Japan.
Seiichi GotoGoto Clinic, Fukuoka, Japan.
Kojiro IchikawaFukutsu Clinic, Fukuoka, Japan.
Kazuo KobayashiDepartment of Clinical Research Support Center, Japan Physicians Association, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGlucagon-like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of the first oral GLP1Ra (oral semaglutide) in Japan since 2021 is expected to expand its usage. The aim of this study is to survey the efficacy and tolerability of oral semaglutide in clinical practice. MATERIALS AND

methodsWe retrospectively analyzed 120 outpatients diagnosed with type 2 diabetes mellitus who had received oral semaglutide for >6 months. Changes in clinical parameters during oral semaglutide treatment from baseline to 12 months were analyzed. The inverse probability weighting method using the propensity score was used to evaluate the differences in clinical parameters at 6 months after treatment, based on the patients' obesity levels.

resultsBody weight (BW), glycated hemoglobin A

conclusionsOral semaglutide treatment demonstrates efficacy and tolerability for managing type 2 diabetes mellitus in Japan. Significant improvements in metabolic factors induced by oral semaglutide are anticipated, particularly in obese patients.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsAdministration, OralAgedBlood GlucoseEast Asian PeopleFemaleGlucagon-Like PeptidesHumansJapanMaleMiddle AgedRetrospective StudiesSemaglutideBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutideGlucagon‐like peptide 1 receptor agonistOral semaglutideTolerability

Identifiers

PMID38700282
PMCPMC11363112

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.